PURPOSE: Metacognitive therapy (MCT) is an effective psychological treatment for a range of emotional disorders. However, the applicability of MCT to treating emotional distress in physical health populations has yet to be tested. The present study examined the potential of MCT for alleviating emotional distress in adolescent and young adult cancer (AYAC) survivors. METHODS: Twelve AYAC survivors, aged 18-23, who had completed acute medical treatment participated in this pilot open trial with 6 months follow-up. Each participant completed a baseline period followed by 8-14 sessions of MCT that targeted perseverative thinking (worry and rumination), attentional control, and metacognitive beliefs. The primary outcome variable was severity of depression and anxiety symptoms as measured by the Hospital Anxiety and Depression Scale (HADS). RESULTS: MCT was associated with large and statistically significant reductions in anxiety, depression, trauma symptoms, and metacognitive beliefs and processes. In the intention-to-treat sample, 50% of participants met standardized criteria for recovery on the HADS at posttreatment and these gains were maintained through to 6-month follow-up. CONCLUSION: MCT is a promising transdiagnostic approach to treating different forms of emotional distress in AYAC survivors. Further investigation in controlled trials is now warranted.
PURPOSE: Metacognitive therapy (MCT) is an effective psychological treatment for a range of emotional disorders. However, the applicability of MCT to treating emotional distress in physical health populations has yet to be tested. The present study examined the potential of MCT for alleviating emotional distress in adolescent and young adult cancer (AYAC) survivors. METHODS: Twelve AYAC survivors, aged 18-23, who had completed acute medical treatment participated in this pilot open trial with 6 months follow-up. Each participant completed a baseline period followed by 8-14 sessions of MCT that targeted perseverative thinking (worry and rumination), attentional control, and metacognitive beliefs. The primary outcome variable was severity of depression and anxiety symptoms as measured by the Hospital Anxiety and Depression Scale (HADS). RESULTS: MCT was associated with large and statistically significant reductions in anxiety, depression, trauma symptoms, and metacognitive beliefs and processes. In the intention-to-treat sample, 50% of participants met standardized criteria for recovery on the HADS at posttreatment and these gains were maintained through to 6-month follow-up. CONCLUSION: MCT is a promising transdiagnostic approach to treating different forms of emotional distress in AYAC survivors. Further investigation in controlled trials is now warranted.
Entities:
Keywords:
anxiety; depression; metacognitive therapy; open trial; traumatic stress symptoms
Authors: Adam R Cassidy; Jane Holmes Bernstein; David C Bellinger; Jane W Newburger; David R DeMaso Journal: Clin Neuropsychol Date: 2018-12-26 Impact factor: 3.535
Authors: Adrian Wells; David Reeves; Calvin Heal; Peter Fisher; Linda Davies; Anthony Heagerty; Patrick Doherty; Lora Capobianco Journal: Front Psychiatry Date: 2020-06-30 Impact factor: 4.157
Authors: Pan Pan Xiao; Si Qing Ding; Ying Long Duan; Xiao Fei Luo; Yi Zhou; Qin Qin Cheng; Xiang Yu Liu; Jian Fei Xie; Andy Sk Cheng Journal: Front Psychol Date: 2022-09-27
Authors: Josefin Hagström; Malin Ander; Martin Cernvall; Brjánn Ljótsson; Henrik W Wiman; Louise von Essen; Joanne Woodford Journal: PeerJ Date: 2020-03-19 Impact factor: 2.984